Meet us at BIO International Convention 2022

> english version Imprint

 

Impressum

 

Sciomics GmbH
Karl-Landsteiner-Str. 6
69151 Neckargemünd
Telefon: +49 6221 4294830
Telefax: +49 6221 4294834
E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Internet: http://www.sciomics.de
Sciomics GmbH wird vertreten durch: Geschäftsführer Dr. Christoph Schröder

 

Registergericht: Amtsgericht Mannheim
Handelsregister
Registernummer: HRB716969

Umsatzsteuer-Identifikationsnummer gemäß § 27a Umsatzsteuergesetz: DE289272460

 

Urheberrecht

Alle Inhalte der Internetpräsenz der Sciomics GmbH sind urheberrechtlich geschützt. Dies gilt für Texte wie auch Fotos, Grafiken sowie PDF-Dokumente.
Jede Vervielfältigung oder Verbreitung dieses Internetangebotes oder auch von Inhalten, Auszügen, Dateien oder anderen Teilen davon, zum Beispiel zum Nachdruck, zur Kopie in andere Internetseiten oder zur Weitergabe in elektronischer Form, bedarf der schriftlichen Genehmigung der Sciomics GmbH.

 

Haftung

Trotz sorgfältiger inhaltlicher Kontrolle übernehmen wir keine Haftung für die Inhalte externer Links. Für den Inhalt der verlinkten Seiten sind ausschließlich deren Betreiber verantwortlich.

 

 

 

Imprint

 

Sciomics GmbH
Karl-Landsteiner-Str. 6
69151 Neckargemünd
Phone: +49 6221 4294830
Fax: +49 6221 4294834
E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Internet: http://www.sciomics.de
Sciomics GmbH is represented by: Geschäftsführer Dr. Christoph Schröder

 

Register jurisdiction: Amtsgericht Mannheim
Commercial Register
Registration number: HRB716969

Umsatzsteuer-Identifikationsnummer (VAT identification number) according to §27a of the Umsatzsteuergesetz (UStG, Sales Tax Law): DE289272460

 

Copyright

The layout, texts, text fragments and graphics used and any other contents on the homepage protected by copyright law. All rights reserved.

 

Liability

Links have been proved during setup. Since information on the WWW is subject of current change Sciomics accepts no responsibility with regard to such problems, or the consequences thereof, incurred as a result of using this site or any linked external sites.
This disclaimer is not intended to contravene any requirements laid down in applicable national law nor to exclude liability for matters which may not be excluded under that law.


 

 

 

 

COVID-19 related activities and services

covid 19 portfolio web

News

New article | Co-Expression of microRNAs and Proteins in Alzheimer’s Disease

| Jan 2022 | In a study by Valentina di Pietro at Birmingham University our scioDoiscover platform was used to analyse the co-expression of proteins and microRNAs in the brains of Alzheimer's disease patients.

Watson, C. N. et al. Co-Expression Analysis of microRNAs and Proteins in Brain of Alzheimer’s Disease Patients. Cells 11, 163 (2022).
New article | ETV6 levels predict outcome in DLBCL

| Jan 2022 | Erich Piovan and collegues at University of Padua collaborated with Sciomics to study specific biomarkers in FFPE tissue samples of DLBCL patients by custom antibody microarrays.

Marino, D. et al. High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients. Cancers 14, (2022).
New article | Biomarker identification and verification in endometriosis

| 22th Oct 2021 | Scientists at University Medical Centre Ljubljana used our scioDiscover platform for a biomarker identification in endometriosis:

"Discovery proteomics using antibody microarrays that covered 1360 proteins identified 16 proteins with different levels in cases versus the control patients. The validation using an ELISA approach confirmed significant differences in the levels of cartilage oligomeric matrix protein (COMP) and transforming growth factor-β-induced protein ig-h3 (TGFBI) and nonsignificant differences in angiotensinogen (AGT). "

 Janša, V. et al. (2021) ‘Proteomic analysis of peritoneal fluid identified COMP and TGFBI as new candidate biomarkers for endometriosis’, Scientific Reports, 11:20870. doi: 10.1038/s41598-021-00299-2. 

biomarkers in endometriosis

 

New article | Parkinson's Disease analysed via brain organoids

| Oct 2021 | In a study led by University of Luxembourg and OrganoTherapeutics SARL-S we used our scioPhospho assay to analyse the reaction of a brain organoid model for Parkinson's disease to certain treatments.

Jarazo, J. et al. (2021) ‘Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2-Hydroxy...’, Movement Disorders, in press: doi: 10.1002/mds.28810 (Please get in touch for fulltext).

 

New article | Selective elimination of immunosuppressive T cells in patients with multiple myeloma

| Feb 2021 | Scientists at Heidelberg University Hospital used our scioCD  platform to profile CD8+SLAMF7+ cell cultures:

"High throughput screening of 351 different cytokines and immune proteins in the supernatants of the T cells cultures revealed strong upregulation of IL-6, IL-8, both vital survival factors for myeloma cells, and CXCL5, a chemokine that could enhance the frequency of CD4 Treg, in the cultures containing CD8+SLAMF7+ cells. IL-2 and IL-5 were upregulated in the control cultures without CD8+SLAMF7+ T cells, highlighting a more activated state in the control group and suggestion IL-6 and IL-8 as potential effector cytokines for the suppressive CD8+SLAMF7+ T cells."

Awwad, M. H. S. et al. (2021) ‘Selective elimination of immunosuppressive T cells in patients with multiple myeloma’, Leukemia, pp. 1–14. doi: 10.1038/s41375-021-01172-x.

 

Testimonials

Dr. Joachim Lupberger 

Institute for Viral and Liver Disease, Inserm U1110, University of Strasbourg, LabEx HepSYS, Strasbourg, France

"Our lab is focusing on the identification of minimal-invasive biomarkers for liver disease progression. A challenge of our humanized animal models for liver disease is the low volume of blood samples available, which did not pose any problem for the analysis. I was pleased by the prompt, friendly, and uncomplicated contact and was impressed by the results and the thorough report we received. The overall quality was excellent, which made us to continue using the service of Sciomics for follow-up projects analyzing patient material."

Product: scioPhospho

 

 Prof. Dr. Andreas Weigert 

Goethe-University Frankfurt, Faculty of Medicine, Institute of Biochemistry I, Frankfurt, Germany

"We were under considerable time pressure to gain comprehensive information about cytokine/chemokine levels in a mouse model of self-resolving inflammation. To add to our misery, we had only a small number of biological replicates to run the analyses. Thankfully, the team at Sciomics were able to come to our rescue by providing a very prompt analysis, without neglecting to properly communicate the procedure, potential caveats and other details. The whole process was a very satisfying experience, rather like working with committed colleagues than with a company, and we got great data out of the project. I do happily recommend working with Sciomics for targeted proteomics analyses."

Product: scioCD

 

Tweets

  • 6 days ago

    Partner with us at #BIO2022 International Convention in San Diego CA and learn about our smart protein biomarker po… https://t.co/kYObhmyG1B

  • 6 days ago

    RT @Fusion_Conf: Final day of the 3rd Cell Death, Cell Stress & Metabolism Conference. We are looking forward to more outstanding talks thi…

  • 6 days ago

    We are here for the 3rd and final day of the 3rd Cell Death, Cell Stress & Metabolism Conference #CDCSM22, at Cancu… https://t.co/g8MUcdyEkm

  • 10 days ago

    En-route to attending 3rd Cell Death, Cell Stress & Metabolism Conference #CDCSM22 Dr Anne Griesbeck will be giving… https://t.co/JrXTQGQoj3

  • 42 days ago

    We would like to welcome our new colleague Barbara Eberbach in our team. Barbara is experienced in setting up new v… https://t.co/VC3S3QXYFL